Journal: Annals of Translational Medicine

Article Title: Antibody microarray analysis of serum inflammatory cytokines in patients with calcific aortic valve disease

doi: 10.21037/atm-20-4463

Figure Lengend Snippet: Primers sequences for RT-PCR

Article Snippet: Then protein samples (20–100 µg) were resolved using SDS-PAGE and then moved to polyvinylidene fluoride (PVDF) membrane (Millipore, USA) with being probed with GAPDH (Proteintech), CXCL13/BLC (RRIDs: AB_1191734), IL-12p40/IL12B (RRIDs: AB_1156284), CXCL9/MIG (RRIDs: AB_2086730) followed by appropriate secondary antibody.

Techniques: Sequencing

Journal: Frontiers in Immunology

Article Title: Targeting asparagine potentiates anti-PD-L1 immunotherapy in gastric cancer by enhancing CD8 + T cell anti-tumor response

doi: 10.3389/fimmu.2025.1626581

Figure Lengend Snippet: (A–C) The in vivo antitumor effect of asparaginase was investigated in an MFC tumor model (n=5 mice per group). Tumor volume was assessed twice weekly, and treatment was initiated when the tumor volume reached approximately 100 mm . (D) The proportion of CD4/CD8 positive cells in the tumor tissue in each group after asparaginase treatment. (E, F) IFN-γ, GZMB, CXCL9 and CXCL10 in tumors were measured by ELISA after asparaginase treatment (n = 5). ** indicates p-value < 0.01, *** indicates p-value < 0.001 and **** indicates p-value < 0.0001.

Article Snippet: The concentrations of mouse IFN-gamma, Granzyme B, CXCL9, and CXCL10 were determined using specific ELISA kits from Mouse IFN-gamma ELISA Kit (Abclonal, RK00019), Mouse Granzymes B ELISA Kit (Abclonal, RK00370), Mouse CXCL 9 ELISA Kit (Abclonal, RK03026), Mouse CXCL10 ELISA Kit (Abclonal, RK00056).

Techniques: In Vivo, Enzyme-linked Immunosorbent Assay

Journal: Advanced Composites and Hybrid Materials

Article Title: PD-1-engineered manganese-based nanoplatform loaded with CXCL9 induces ICD and intensifies T-cell infiltration for melanoma treatment

doi: 10.1007/s42114-025-01321-1

Figure Lengend Snippet: Fig. 2 Characterization of BPC9@MnCO3. A TEM images of MnCO3. B TEM images revealing morphologi- cal features and EDX elemental maps showing spatial distribu- tion of Mn, C, and O. C SEM images of MnCO3 and BPC9@ MnCO3. D SDS-PAGE images of BPC9@MnCO3, BP@ MnCO3, and CXCL9 protein profiles. E Mean diameter of BPC9@MnCO3, BP@MnCO3, and MnCO3 (n = 3). F TEM images of MnCO3 NPs degrada- tion at different pH. G Ultra- violet absorption spectra of MB of MnCO3 in different types of solutions. H Absorption spectra of different MnCO3 concentra- tion solutions mixed with MB. I Absorption spectra of different H2O2 concentration solutions mixed with MB

Article Snippet: Specifically, we obtained CXCL9 and the experimental compound AMG487 from MedChemExpress, while lentiviral vectors were procured from Haixing Biosciences.

Techniques: SDS Page, Concentration Assay

Journal: Advanced Composites and Hybrid Materials

Article Title: PD-1-engineered manganese-based nanoplatform loaded with CXCL9 induces ICD and intensifies T-cell infiltration for melanoma treatment

doi: 10.1007/s42114-025-01321-1

Figure Lengend Snippet: Fig. 4 Engineering tumor cell membrane PD-L1 pre-binding ability and CXCL9 lymphocyte chemotaxis ability. A Schematic of BP@MnCO3 competitively occupies PD-L1 binding sites on tumor cells. Created in https://BioRender.com. B, C PD-L1 expression on B16-F10 cells after co-culture with PBS, BM@MnCO3, or BP@MnCO3 (n = 3). D, E Representative flow cytometry profiles and corresponding quantifications of percentages of CD8+ T cells in the lower compartment after 2-h treatment with differ- ent CXCL9 preparations (n = 4). F, G Representative flow cytometric histogram of CD4.+ T in the lower chamber after 2-h treatment with different CXCL9 preparations and correspond- ing quantitative analysis (n = 4). H Schematic diagram of experimental procedures for the determination of T-cell chemo- taxis in vitro, to demonstrate the effect of CXCL9 released BPC9@MnCO3 on T-cell chemotaxis. I Relative T-cell migration rates across treatment groups (n = 3). ns, no signifi- cant; **p < 0.01; ***p < 0.001; ****p < 0.0001

Article Snippet: Specifically, we obtained CXCL9 and the experimental compound AMG487 from MedChemExpress, while lentiviral vectors were procured from Haixing Biosciences.

Techniques: Membrane, Binding Assay, Chemotaxis Assay, Expressing, Co-Culture Assay, Flow Cytometry, In Vitro, Migration